A Beta-only IL-2 ImmunoTherapY Study
Recruiting now · Phase 1/Phase 2
Conditions studied: Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
In brief
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Key facts
- Study ID
- NCT05086692
- Run by
- Medicenna Therapeutics, Inc.
- People needed
- 115
- Starts
- 2021-08-27
- Expected to finish
- 2026-12-30
- Last updated by the study team
- 2025-07-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hospital Universitario de Torrejon — Torrejón, Spain (enrolling)
- Hospital de la Santa Creu i Sant Pau — Barcelona, Spain (enrolling)
- Hospital Universitario Ramón y Cajal — Madrid, Spain (enrolling)
- START Madrid / Hospital Universitario Fundacion Jimenez Diaz — Madrid, Spain (enrolling)
- Hospital Universitario Hm Sanchinarro — Madrid, Spain (enrolling)
- Hospital Universitario Central de Asturias (HUCA) — Oviedo, Spain (enrolling)
- Sharp Memorial Hospital — San Diego, California, United States (enrolling)
- Providence Saint John's Health Center — Santa Monica, California, United States (enrolling)
- Boca Raton Regional Hospital — Boca Raton, Florida, United States (enrolling)
- Emory - Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
- Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
- Scientia Clinical Research — Randwick, New South Wales, Australia (enrolling)
- Macquarie University — Sydney, New South Wales, Australia (enrolling)
- University of the Sunshine Coast — Buderim, Queensland, Australia (enrolling)
- Gallipoli Medical Research Foundation — Greenslopes, Queensland, Australia (enrolling)
- Princess Margaret Cancer Center — Toronto, Ontario, Canada (enrolling)
- Mater Misericordiae University Hospital — Dublin, Ireland (enrolling)
- START Lisbon - Centro de Ensaios Clínicos, ULS Sta Maria — Lisbon, Portugal (enrolling)
- Instituto Portugues De Oncologia Do Porto — Porto, Portugal (enrolling)
- Institut Catala d'Oncologia (ICO)-Badalona — Badalona, Spain (enrolling)
- START Barcelona / HM Nou Delfos — Barcelona, Spain (enrolling)
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California, United States
- Samsung Medical Center — Seoul, Gangnam-gu, South Korea
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea
- The Catholic University of Korea St. Vincent Hospital — Suwon, Gyeonggi-do, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.